Searched for
US PHARMA TARIFFS
Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investorsDonald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analys...- Indian pharma firms may yet survive Trump's 200% tariff bombshellDonald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say...
- 200% Trump tariff shock? India’s cheap pills may still beat US rivalsUS President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical expor...
- Trump’s 100% generic drug duty threatens US low-cost supplyPresident Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028...
- Why is market falling today? 7 triggers behind 800-point Sensex fall, Rs 4 lakh crore wealth wipeoutIndian stock markets experienced a decline on Wednesday as tensions in the Middle East escalated. Crude oil prices surged above $92 a barre...
- India's gem and jewellery exports rise 26.5% in June, shining at $2.21 billionIndia's gem and jewellery exports saw a significant rebound in June, increasing by 26.5 percent. Lower international gold prices and improv...
- Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% stormTrump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...
- Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?The United States is set to implement a phased approach to tariffs on generic drug imports, beginning at zero percent and escalating to one...
- Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...
- Sun Pharma, Cipla & other pharma stocks shed over 2% as Trump announces up to 200% tariffs on generic drugs from 2028Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff...
- Parliament Watch: FM on rupee, `16.1 lakh cr fuel taxes, India-US trade talks and moreRupee depreciation is influenced by rising crude oil prices and reduced capital account support. India monitors US trade policy changes and...
- India engaged with the US, studying all the developments: Govt tells ParliamentThe government told Parliament it is closely monitoring developments in its trade relationship with the US and remains engaged with Washing...
- Index returns likely to be slightly above long-term averages over next 2 years: Mirae Asset CIO Neelesh Surana on market outlook, fund strategiesMirae Asset Investment Managers (India)’s equity funds have experienced a period of underperformance—the first major blip since inception i...
- Stocks, gold and debt: Why ICICI Pru’s Dharmesh Kakkad favours a multi-asset strategy nowICICI Prudential's Dharmesh Kakkad advises investors against chasing the best-performing asset classes, arguing that a dynamic multi-asset ...
- Ahead of Market: 10 things that will decide stock market action on ThursdayIndian equities posted their steepest single-day decline since March as rising crude prices, renewed Middle East tensions and weak global c...
- Cost pressure to keep Q1 profit growth muted for Nifty 50 companiesNifty 50 companies anticipate double-digit revenue growth for the June 2026 quarter. Profit growth is projected to remain in single digits ...
- Ahead of Market: 10 things that will decide stock market action on WednesdayIndian equities ended lower after four straight gains as profit booking, weak global cues and caution ahead of the US Fed minutes weighed o...
- India's defence export boom could hit ₹65,000 crore by 2030; pvt sector startups the real play: Sunil SubramaniamIndia's defence exports are poised to surpass government targets, reaching ₹60,000-65,000 crore by 2030, according to market expert Sunil S...
- 'Not a great environment for Indian market': Harsha Upadhyaya on Iran-US tensions, IT outlook, pharma bet, and where to be cautiousGlobal challenges are impacting Indian stocks. West Asian tensions and rising US inflation create headwinds. Tech sector shifts also affect...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
Load More
